Hsbc Holdings PLC Reduces Stock Position in Illumina, Inc. $ILMN

Hsbc Holdings PLC cut its position in Illumina, Inc. (NASDAQ:ILMN) by 7.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 112,618 shares of the life sciences company’s stock after selling 9,627 shares during the period. Hsbc Holdings PLC’s holdings in Illumina were worth $13,895,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ILMN. Invesco Ltd. increased its holdings in Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after buying an additional 1,352,731 shares during the period. AQR Capital Management LLC increased its stake in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after acquiring an additional 1,028,099 shares during the period. Morgan Stanley raised its holdings in shares of Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after purchasing an additional 1,005,474 shares during the last quarter. Vaughan Nelson Investment Management L.P. acquired a new position in Illumina during the first quarter valued at $106,462,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Illumina in the 4th quarter valued at about $73,532,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the transaction, the insider directly owned 20,953 shares in the company, valued at $3,771,540. The trade was a 2.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at $2,243,394.60. This trade represents a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on the company. Sanford C. Bernstein assumed coverage on Illumina in a report on Friday, June 26th. They set a “market perform” rating and a $185.00 target price on the stock. Leerink Partners upped their price objective on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Canaccord Genuity Group raised their price objective on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a report on Thursday, May 14th. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Nine analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $156.88.

Illumina Stock Down 0.9%

ILMN stock opened at $190.87 on Thursday. The firm has a 50-day simple moving average of $169.14 and a 200-day simple moving average of $144.62. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $196.66. The stock has a market capitalization of $28.88 billion, a P/E ratio of 34.70, a P/E/G ratio of 2.84 and a beta of 1.47. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts forecast that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.